RxDoctor Payments Data

John Bowden, MD

Dermatology · Santa Fe, NMNPI 1831158385

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.7% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 45.4% of the total.

$3,119in general payments, 2019–2025

Across 152 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$387
  • Incyte Corporation$340
  • Regeneron Healthcare Solutions, Inc.$294
  • Sanofi$220
  • Revance Therapeutics, Inc.$121
  • plus $340 from 7 others

What the payments were for

  • Food & beverage$3,04798%
  • Education$722%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,119 in reported general payments places this provider in the 75th percentile of 52 dermatology providers in New Mexico.

See all dermatology providers in New Mexico

Medicare billing

Part B allowed, 2024
$250,328
Medicare patients
1,153
Services billed
4,236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib19$137,030
Fluorouracil124$7,326
Betamethasone Dipropionate94$2,836
Doxycycline Hyclate85$2,311
ValacyclovirValacyclovir Hcl35$2,150
Mometasone Furoate71$1,901
Tretinoin19$1,690
Triamcinolone Acetonide144$1,525
Clobetasol Propionate45$1,398
Metronidazole15$874
Minoxidil93$836
Spironolactone35$735
Ketoconazole52$659
Finasteride78$617
Fluconazole39$588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,417$137,03019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 52 dermatology providers in New Mexico.

Other dermatology in Santa Fe

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →